[{"id":"68078b0d-d5ab-4473-9bbc-13859ce40855","acronym":"","url":"https://clinicaltrials.gov/study/NCT06037317","created_at":"2023-09-14T14:12:50.055Z","updated_at":"2024-07-02T16:35:21.175Z","phase":"Phase 1","brief_title":"A Study of SY-3505 in Patients With Advanced LTK Fusion-Positive Solid Tumors","source_id_and_acronym":"NCT06037317","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" LTK","pipe":"","alterations":" ","tags":["LTK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ficonalkib (SY-3505)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 05/30/2024","start_date":" 05/30/2024","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 05/30/2026","study_completion_date":" 05/30/2026","last_update_posted":"2024-02-02"},{"id":"0de3d8d0-74d3-4f68-b14d-17316723833a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05869162","created_at":"2023-05-22T16:05:42.039Z","updated_at":"2024-07-02T16:35:38.961Z","phase":"Phase 2","brief_title":"Phase II Study of SY-3505 in Patients With ALK-positive NSCLC Who Have Failed Prior Second-Generation ALK TKI","source_id_and_acronym":"NCT05869162","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive • ALK fusion","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ficonalkib (SY-3505)"],"overall_status":"Recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 06/30/2023","start_date":" 06/30/2023","primary_txt":" Primary completion: 06/10/2025","primary_completion_date":" 06/10/2025","study_txt":" Completion: 06/10/2025","study_completion_date":" 06/10/2025","last_update_posted":"2023-08-25"},{"id":"22c9541b-c7e7-4b2e-8b7a-6c0e37b47733","acronym":"","url":"https://clinicaltrials.gov/study/NCT05257512","created_at":"2023-02-14T20:01:43.671Z","updated_at":"2024-07-02T16:35:55.599Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT05257512","lead_sponsor":"Shouyao Holdings (Beijing) Co. LTD","biomarkers":" ALK","pipe":" | ","alterations":" ALK positive","tags":["ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ficonalkib (SY-3505)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/26/2020","start_date":" 04/26/2020","primary_txt":" Primary completion: 04/26/2024","primary_completion_date":" 04/26/2024","study_txt":" Completion: 08/26/2024","study_completion_date":" 08/26/2024","last_update_posted":"2023-02-14"}]